Company information - Licensing agreement with Hepalys (Details) € in Millions, $ in Millions |
1 Months Ended | ||||
|---|---|---|---|---|---|
|
Nov. 30, 2023
USD ($)
|
Nov. 30, 2023
EUR (€)
|
Dec. 31, 2025 |
Sep. 26, 2023 |
Sep. 20, 2023 |
|
| South Korea | |||||
| Collaborative Arrangements | |||||
| Option to acquire shares in company, percentage | 30.00% | ||||
| Percentage of patients with significant fibrosis | 15.00% | ||||
| Maximum | Japan | |||||
| Collaborative Arrangements | |||||
| Percentage of population suffering from NASH | 2.70% | ||||
| Maximum | South Korea | |||||
| Collaborative Arrangements | |||||
| Percentage of population suffering from NASH | 5.20% | ||||
| Hepalys Pharma, Inc | Catalys Option Agreement | |||||
| Collaborative Arrangements | |||||
| Option to acquire shares in company, percentage | 30.00% | 30.00% | |||
| Revenue from recognition of fair value of shares acquired | $ 3.6 | € 3.4 | |||
| Hepalys Pharma, Inc | Hepalys Pharma, Inc | |||||
| Collaborative Arrangements | |||||
| Revenue from upfront payments | $ 10.0 | € 9.3 | |||